This page shows the publications co-authored by Nir Hacohen and Michael Filbin.
Plasma P-selectin is an early marker of thromboembolism in COVID-19. medRxiv. 2021 Jul 14.
Plasma from patients with bacterial sepsis or severe COVID-19 induces suppressive myeloid cell production from hematopoietic progenitors in vitro. Sci Transl Med. 2021 06 16; 13(598).
Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. 2021 May 18; 2(5):100287.
Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patients. bioRxiv. 2020 Nov 03.
Induction of a regulatory myeloid program in bacterial sepsis and severe COVID-19. bioRxiv. 2020 Sep 02.
An immune-cell signature of bacterial sepsis. Nat Med. 2020 03; 26(3):333-340.
SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. J Clin Invest. 2021 07 01; 131(13).
Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19. bioRxiv. 2021 May 12.
Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infect Dis. 2021 Aug; 8(8):ofab153.
SARS-CoV-2 Viremia is Associated with Distinct Proteomic Pathways and Predicts COVID-19 Outcomes. medRxiv. 2021 Feb 26.
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020 11 27; 370(6520).
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.